**This commentary refers to 'The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation', by Steffel *et al*., 2018, pages 1330--1393.**

In the updated guide on NOAC use in patients with non-valvular atrial fibrillation, the European Heart Rhythm Association recommends against the use of the antiepileptic drug, levetiracetam, due to potential P-glycoprotein-mediated drug--drug interaction (DDI).[@ehy780-B1] While the summary of product characteristics of apixaban, and edoxaban list phenytoin, carbamazepine, and phenobarbital, and dabigatran's lists phenytoin and carbamazepine, none lists levetiracetam as a P-gp inducer.

In a Phase I trial, healthy volunteers received concomitant levetiracetam and digoxin, a P-gp substrate.[@ehy780-B2] Administration of a P-gp inducer with digoxin would be expected to decrease digoxin plasma concentrations; however, repeated levetiracetam exposure had no effect on digoxin steady-state pharmacokinetics.[@ehy780-B2] Absence of effect on digoxin pharmacodynamics, as measured by ECG parameters, supports this lack of interaction.[@ehy780-B2] P-gp and CYP450 enzyme expression induction by xenobiotics is primarily mediated by the pregnane X receptor (PXR). Since levetiracetam does not induce CYP450 enzyme expression, as supported by clinical data,[@ehy780-B3] it is unlikely to activate PXR, and therefore, induce P-gp expression. Finally, levetiracetam has no effect on the expression, or function of the products of the ABC transporter genes, ABCB1 (coding for P-gp), ABCC1, ABCC2, and ABCG2, in human cell lines.[@ehy780-B4] Importantly, P-gp function is species-specific; levetiracetam is a substrate of mouse, but not of rat or human P-gp.[@ehy780-B5] Data obtained in non-human models may not be relevant to humans.

The recommendation appears to be solely based on results from *in vivo* animal models. However, clinical data, which supersede animal model data, demonstrate that levetiracetam is not a P-gp inducer. Evidence presented here support the absence of any clinically relevant DDI between levetiracetam and NOACs. The recommendation could potentially constitute a serious safety risk for patients treated concomitantly with levetiracetam and a NOAC, if levetiracetam is substituted.
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